Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica

Nobuyoshi, Sho; Kanamori, Akira; Matsumoto, Yoshiko; Nakamura, Makoto

doi:10.1007/s10384-016-0454-0

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8) Clinically, IVIg has been an established treatment in neurological diseases such as Guil-lain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN) and myasthenia gravis (MG) in addition to Kawasaki disease (KD). 9) Recent reports demonstrate that IVIg achieved visual improvement in the corticosteroid-refractory optic neuritis in MS. 10) Given these reports, it is possible that IVIg will become an alternative option for the treatment of optic neuritis.…”

Section: Introductionmentioning

confidence: 99%

Prophylactic Treatment with Intravenous Immunoglobulin Attenuates Experimental Optic Neuritis in Mice

Takahashi

Okuda

Tamura

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Optic neuritis is characterized by optic nerve inflammation, demyelination and axonal loss. Intravenous immunoglobulin (IVIg) has been reported to be effective for steroid-resistant patients. However, there is no report investigating the histopathological efficacy of IVIg in optic neuritis models. In this study, we examined the effects of IVIg on optic neuritis of experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune optic neuritis (EAON). Inflammation, demyelination and axonal loss were assessed in the optic nerve sections. IVIg showed dose-dependent prevention of clinical symptoms in EAON. IVIg provided an anti-inflammatory effect in both EAE and EAON, associated with improved demyelination. Axonal loss in EAE was also significantly attenuated. These results suggest that IVIg has neuroprotective properties in experimental optic neuritis, and is a promising new treatment for optic neuritis.

show abstract

Section: Introductionmentioning

confidence: 99%

Prophylactic Treatment with Intravenous Immunoglobulin Attenuates Experimental Optic Neuritis in Mice

Takahashi

Okuda

Tamura

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study

et al. 2021

View full text Add to dashboard Cite

Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)

Shen

2023

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica

Abstract: IVIG administration reduced optic nerve degeneration in a rat model of NMO-optic neuritis. IVIG could be used as a treatment in the acute phase of NMO.

Cited by 5 publications

References 18 publications

Prophylactic Treatment with Intravenous Immunoglobulin Attenuates Experimental Optic Neuritis in Mice

Prophylactic Treatment with Intravenous Immunoglobulin Attenuates Experimental Optic Neuritis in Mice

Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study

Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)

Contact Info

Product

Resources

About